Aimed at the biotechnology and pharma market, the document highlights northern England as an attractive location for life sciences investment, as perceived by some of the region’s key players.
This special feature section, entitled ‘Innovation UK: Pushing life science frontiers in the North of England’, follows a successful trip to the US-based BIO International Convention earlier this summer by a Northern Powerhouse life sciences delegation.
The delegation included MAHSC, Alderley Park (Manchester Science Partnerships), Redx Pharma, the Northern Health Science Alliance (NHSA) and Aptus Clinical. Bionow backed the delegation.
As well as space devoted to each organisation, the 16 page extra contains a summary of the group’s roundtable discussion, at the convention, on the impact of location on R&D strategies. The supplement is featured in Scrip Intelligence’s weekly email news update (12/8), available on the free part of their website and being sent by them to 10,000 of their global marketing contacts.
MAHSC Director, Professor Ian Greer, commented ‘It is crucial that we continue to play our part in ‘banging the drum’ for the North of England life sciences, particularly post Brexit, to reassure partners that the region, and the UK, are still very much open for business.’
Dr Linda Magee, MAHSC Business Development Director, represented MAHSC at BIO and identifies Greater Manchester’s key benefits as a life sciences inward investment location:
- MAHSC’s ambitious targets and research expertise, processes and infrastructure
- Acceleration of health innovations through devolution of the annual £6bn NHS budget
- Strategic resources and connections within the Northern Powerhouse to leverage opportunities
Linda Magee can be contacted by email on email@example.com or on tel: +44 (0)161 306 0639.